Literature DB >> 20811979

Use of inhibitors in the study of MAP kinases.

Kimberly Burkhard1, Paul Shapiro.   

Abstract

The mitogen-activated protein (MAP) kinases are ubiquitous intracellular signaling proteins that respond to a variety of extracellular signals and regulate most cellular functions including proliferation, apoptosis, migration, differentiation, and secretion. The four major MAP kinase family members, which include the ERK1/2, JNK, p38, and ERK5 proteins, coordinate cellular responses by phosphorylating and regulating the activity of dozens of substrate proteins involved in transcription, translation, and changes in cellular architecture. Uncontrolled activation of the MAP kinases has been implicated in the initiation and progression of a variety of cancers and inflammatory disorders. As such, the ability to manipulate the activity of MAP kinase proteins with specific pharmacological inhibitors has received much attention as research tools for understanding basic mechanisms of cellular functions and for clinical tools to treat diseases. A variety of pharmacological inhibitors have been developed to selectively block MAP kinases directly or indirectly through targeting upstream regulators. This chapter will provide an overview of some of the current inhibitors that target MAP kinase signaling pathways and provide methodology on how to use selective MAP kinase inhibitors and immunoblotting techniques to monitor and quantify phosphorylation of MAP kinase substrates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811979      PMCID: PMC3727897          DOI: 10.1007/978-1-60761-795-2_6

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  27 in total

1.  Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Authors:  S P Davies; H Reddy; M Caivano; P Cohen
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

2.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.

Authors:  B L Bennett; D T Sasaki; B W Murray; E C O'Leary; S T Sakata; W Xu; J C Leisten; A Motiwala; S Pierce; Y Satoh; S S Bhagwat; A M Manning; D W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.

Authors:  J C Lee; J T Laydon; P C McDonnell; T F Gallagher; S Kumar; D Green; D McNulty; M J Blumenthal; J R Heys; S W Landvatter; J E Strickler; M M McLaughlin; I R Siemens; S M Fisher; G P Livi; J R White; J L Adams; P R Young
Journal:  Nature       Date:  1994 Dec 22-29       Impact factor: 49.962

Review 4.  Farnesyltransferase inhibitors.

Authors:  S M Hahn; E Bernhard; W G McKenna
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

5.  The specificities of protein kinase inhibitors: an update.

Authors:  Jenny Bain; Hilary McLauchlan; Matthew Elliott; Philip Cohen
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

6.  SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1.

Authors:  A Cuenda; J Rouse; Y N Doza; R Meier; P Cohen; T F Gallagher; P R Young; J C Lee
Journal:  FEBS Lett       Date:  1995-05-08       Impact factor: 4.124

7.  Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

Authors:  James A McCubrey; Michele Milella; Agostino Tafuri; Alberto M Martelli; Paolo Lunghi; Antonio Bonati; Melchiorre Cervello; John T Lee; Linda S Steelman
Journal:  Curr Opin Investig Drugs       Date:  2008-06

Review 8.  The BCR-ABL story: bench to bedside and back.

Authors:  Stephane Wong; Owen N Witte
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

9.  Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.

Authors:  John Regan; Steffen Breitfelder; Pier Cirillo; Thomas Gilmore; Anne G Graham; Eugene Hickey; Bernhard Klaus; Jeffrey Madwed; Monica Moriak; Neil Moss; Chris Pargellis; Sue Pav; Alfred Proto; Alan Swinamer; Liang Tong; Carol Torcellini
Journal:  J Med Chem       Date:  2002-07-04       Impact factor: 7.446

10.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04
View more
  8 in total

1.  TNF-α-mediated suppression of Leydig cell steroidogenesis involves DAX-1.

Authors:  Mohanraj Sadasivam; Balamurugan Ramatchandirin; Sivasangari Balakrishnan; Chidambaram Prahalathan
Journal:  Inflamm Res       Date:  2015-06-06       Impact factor: 4.575

2.  Role of Polo-like kinase 1 in the regulation of the action of p31comet in the disassembly of mitotic checkpoint complexes.

Authors:  Sharon Kaisari; Pnina Shomer; Tamar Ziv; Danielle Sitry-Shevah; Shirly Miniowitz-Shemtov; Adar Teichner; Avram Hershko
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-22       Impact factor: 11.205

Review 3.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

4.  The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson's disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway.

Authors:  Piniel Alphayo Kambey; Ma Chengcheng; Guo Xiaoxiao; Ayanlaja Abiola Abdulrahman; Kouminin Kanwore; Iqra Nadeem; Wu Jiao; Dianshuai Gao
Journal:  Metab Brain Dis       Date:  2021-01-28       Impact factor: 3.584

5.  5,6,7,3',4',5'-Hexamethoxyflavone inhibits growth of triple-negative breast cancer cells via suppression of MAPK and Akt signaling pathways and arresting cell cycle.

Authors:  Natasha Borah; Shimara Gunawardana; Haydee Torres; Susan McDonnell; Severine Van Slambrouck
Journal:  Int J Oncol       Date:  2017-10-13       Impact factor: 5.650

6.  A Highly Selective In Vitro JNK3 Inhibitor, FMU200, Restores Mitochondrial Membrane Potential and Reduces Oxidative Stress and Apoptosis in SH-SY5Y Cells.

Authors:  Stephanie Cristine Hepp Rehfeldt; Stefan Laufer; Márcia Inês Goettert
Journal:  Int J Mol Sci       Date:  2021-04-02       Impact factor: 5.923

7.  Histone H2A monoubiquitylation and p38-MAPKs regulate immediate-early gene-like reactivation of latent retrovirus HTLV-1.

Authors:  Anurag Kulkarni; Graham P Taylor; Robert J Klose; Christopher J Schofield; Charles Rm Bangham
Journal:  JCI Insight       Date:  2018-10-18

Review 8.  Role of MAPK/MNK1 signaling in virus replication.

Authors:  Ram Kumar; Nitin Khandelwal; Riyesh Thachamvally; Bhupendra Nath Tripathi; Sanjay Barua; Sudhir Kumar Kashyap; Sunil Maherchandani; Naveen Kumar
Journal:  Virus Res       Date:  2018-06-01       Impact factor: 3.303

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.